| 17alpha-ethynylestradiol | increases expression | EXP | | 6480464 | Ethinyl Estradiol results in increased expression of SPARC mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SPARC mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | decreases expression | ISO | RGD:3742 | 6480464 | Ethinyl Estradiol results in decreased expression of SPARC mRNA | CTD | PMID:17557909 |
| 17alpha-ethynylestradiol | affects expression | ISO | RGD:3742 | 6480464 | Ethinyl Estradiol affects the expression of SPARC mRNA | CTD | PMID:16079270 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:731035 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SPARC mRNA | CTD | PMID:11489354 PMID:20106945 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of SPARC mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:731035 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SPARC mRNA | CTD | PMID:11489354 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:731035 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SPARC mRNA | CTD | PMID:20106945 PMID:11489354 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:3742 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SPARC mRNA | CTD | PMID:11752688 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of SPARC mRNA | CTD | PMID:17942748 |
| 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] | CTD | PMID:18200517 |
| 2,4,6-trinitrobenzenesulfonic acid | increases expression | EXP | | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA | CTD | PMID:17994277 PMID:18200517 |
| 2,4,6-trinitrobenzenesulfonic acid | increases expression | EXP | | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA | CTD | PMID:18200517 PMID:17994277 |
| 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | EXP | | 6480464 | Tretinoin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA]; more ... | CTD | PMID:17994277 |
| 3,3',4,4',5-pentachlorobiphenyl | increases expression | ISO | RGD:3742 | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of SPARC mRNA | CTD | PMID:20959002 |
| 3H-1,2-dithiole-3-thione | decreases expression | ISO | RGD:3742 | 6480464 | 1,2-dithiol-3-thione results in decreased expression of SPARC mRNA | CTD | PMID:19162173 |
| 4,4'-diaminodiphenylmethane | decreases expression | EXP | | 6480464 | 4,4'-diaminodiphenylmethane results in decreased expression of SPARC mRNA | CTD | PMID:18648102 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:731035 | 6480464 | decitabine inhibits the reaction [DNMT3A protein binds to SPARC promoter] | CTD | PMID:19177197 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:731035 | 6480464 | [decitabine affects the methylation of SPARC promoter] which affects the expression of SPARC mRNA | CTD | PMID:18458674 PMID:18458674 |
| 5-aza-2'-deoxycytidine | increases expression | ISO | RGD:731035 | 6480464 | decitabine results in increased expression of SPARC mRNA | CTD | PMID:17397030 PMID:19177197 |
| 5-aza-2'-deoxycytidine | increases expression | ISO | RGD:731035 | 6480464 | decitabine results in increased expression of SPARC mRNA | CTD | PMID:19177197 PMID:17397030 |
| 5-aza-2'-deoxycytidine | increases expression | ISO | RGD:731035 | 6480464 | decitabine results in increased expression of SPARC protein | CTD | PMID:19177197 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:731035 | 6480464 | [decitabine affects the methylation of SPARC promoter] which affects the susceptibility to Fluorouracil; more ... | CTD | PMID:18458674 |
| 5-fluorouracil | multiple interactions | ISO | RGD:731035 | 6480464 | [decitabine affects the methylation of SPARC promoter] which affects the susceptibility to Fluorouracil | CTD | PMID:18458674 |
| 5-fluorouracil | increases response to substance | ISO | RGD:731035 | 6480464 | SPARC protein results in increased susceptibility to Fluorouracil | CTD | PMID:15902309 |
| acetylsalicylic acid | multiple interactions | ISO | RGD:731035 | 6480464 | Aspirin inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY analog results in increased secretion of SPARC protein] | CTD | PMID:17303692 |
| alendronic acid | affects expression | ISO | RGD:3742 | 6480464 | Alendronate affects the expression of SPARC mRNA | CTD | PMID:16079270 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | Tretinoin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] | CTD | PMID:17994277 |
| ammonium chloride | affects expression | ISO | RGD:3742 | 6480464 | Ammonium Chloride affects the expression of SPARC mRNA | CTD | PMID:16483693 |
| arachidonic acid | decreases expression | ISO | RGD:731035 | 6480464 | Arachidonic Acid results in decreased expression of SPARC mRNA | CTD | PMID:16704987 |
| benzene | multiple interactions | ISO | RGD:3742 | 6480464 | [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in decreased expression of SPARC mRNA | CTD | PMID:17905399 |
| benzo[a]pyrene | multiple interactions | EXP | | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in increased expression of SPARC mRNA | CTD | PMID:21715664 |
| benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of SPARC mRNA | CTD | PMID:22610609 |
| cadmium atom | decreases expression | ISO | RGD:731035 | 6480464 | Cadmium results in decreased expression of SPARC mRNA | CTD | PMID:20570719 |
| cadmium dichloride | decreases expression | ISO | RGD:731035 | 6480464 | Cadmium Chloride results in decreased expression of SPARC mRNA; more ... | CTD | PMID:20837119 |
| calciol | multiple interactions | ISO | RGD:731035 | 6480464 | [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein | CTD | PMID:17692823 |
| calcitriol | increases expression | ISO | RGD:3742 | 6480464 | Calcitriol results in increased expression of SPARC protein | CTD | PMID:19092814 |
| carmustine | affects response to substance | ISO | RGD:731035 | 6480464 | SPARC mRNA affects the susceptibility to Carmustine | CTD | PMID:16365179 |
| chlorpyrifos | decreases expression | EXP | | 6480464 | Chlorpyrifos results in decreased expression of SPARC mRNA | CTD | PMID:20350560 |
| choline | multiple interactions | EXP | | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SPARC mRNA | CTD | PMID:20938992 |
| copper atom | multiple interactions | EXP | | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPARC mRNA | CTD | PMID:15467011 |
| copper atom | decreases secretion | EXP | | 6480464 | Copper results in decreased secretion of SPARC protein | CTD | PMID:19635393 |
| copper atom | increases expression | ISO | RGD:731035 | 6480464 | Copper results in increased expression of SPARC mRNA | CTD | PMID:16629173 |
| copper(0) | multiple interactions | EXP | | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of SPARC mRNA | CTD | PMID:15467011 |
| copper(0) | decreases secretion | EXP | | 6480464 | Copper results in decreased secretion of SPARC protein | CTD | PMID:19635393 |
| copper(0) | increases expression | ISO | RGD:731035 | 6480464 | Copper results in increased expression of SPARC mRNA | CTD | PMID:16629173 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] | CTD | PMID:18200517 |
| cyclophosphamide | decreases expression | EXP | | 6480464 | Cyclophosphamide results in decreased expression of SPARC mRNA | CTD | PMID:15331540 |
| cyclophosphamide | increases expression | ISO | RGD:731035 | 6480464 | Cyclophosphamide results in increased expression of SPARC mRNA | CTD | PMID:17403535 |
| cyclosporin A | decreases expression | ISO | RGD:731035 | 6480464 | Cyclosporine results in decreased expression of SPARC mRNA | CTD | PMID:20106945 |
| cytarabine | decreases expression | ISO | RGD:731035 | 6480464 | Cytarabine results in decreased expression of SPARC mRNA | CTD | PMID:21198554 |
| D-glucose | decreases expression | ISO | RGD:731035 | 6480464 | Glucose results in decreased expression of SPARC mRNA | CTD | PMID:19924377 |
| D-glucose | multiple interactions | ISO | RGD:731035 | 6480464 | cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of SPARC mRNA] | CTD | PMID:19924377 |
| diuron | increases expression | ISO | RGD:3742 | 6480464 | Diuron results in increased expression of SPARC mRNA | CTD | PMID:21551480 |
| doxorubicin | increases expression | ISO | RGD:731035 | 6480464 | Doxorubicin results in increased expression of SPARC mRNA | CTD | PMID:15870702 |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of SPARC mRNA | CTD | PMID:15033991 |
| ethanol | increases expression | ISO | RGD:731035 | 6480464 | Ethanol results in increased expression of SPARC mRNA | CTD | PMID:15963989 |
| folic acid | multiple interactions | EXP | | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SPARC mRNA | CTD | PMID:20938992 |
| furosemide | increases expression | ISO | RGD:3742 | 6480464 | Furosemide results in increased expression of SPARC mRNA | CTD | PMID:16526316 |
| glucose | decreases expression | ISO | RGD:731035 | 6480464 | Glucose results in decreased expression of SPARC mRNA | CTD | PMID:19924377 |
| glucose | multiple interactions | ISO | RGD:731035 | 6480464 | cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased expression of SPARC mRNA] | CTD | PMID:19924377 |
| glycerol 2-phosphate | multiple interactions | ISO | RGD:731035 | 6480464 | [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein | CTD | PMID:17692823 |
| indomethacin | multiple interactions | EXP | | 6480464 | Indomethacin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of SPARC mRNA] | CTD | PMID:17994277 |
| L-ascorbic acid | multiple interactions | ISO | RGD:731035 | 6480464 | [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein | CTD | PMID:17692823 |
| L-methionine | multiple interactions | EXP | | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SPARC mRNA | CTD | PMID:20938992 |
| losartan | decreases expression | ISO | RGD:3742 | 6480464 | Losartan results in decreased expression of SPARC mRNA | CTD | PMID:15100363 |
| magnesium atom | increases expression | ISO | RGD:731035 | 6480464 | Magnesium results in increased expression of SPARC protein | CTD | PMID:10397942 |
| methylmercury(1+) | increases expression | ISO | RGD:3742 | 6480464 | methylmercury II results in increased expression of SPARC mRNA | CTD | PMID:17905399 |
| methylmercury(1+) | multiple interactions | ISO | RGD:3742 | 6480464 | [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in decreased expression of SPARC mRNA | CTD | PMID:17905399 |
| N-ethyl-N-nitrosourea | increases expression | ISO | RGD:3742 | 6480464 | Ethylnitrosourea results in increased expression of SPARC mRNA | CTD | PMID:15954086 |
| N-methyl-N'-nitro-N-nitrosoguanidine | decreases expression | ISO | RGD:731035 | 6480464 | Methylnitronitrosoguanidine results in decreased expression of SPARC mRNA | CTD | PMID:12634122 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:3742 | 6480464 | Diethylnitrosamine results in increased expression of SPARC mRNA | CTD | PMID:19638242 |
| paclitaxel | increases expression | ISO | RGD:731035 | 6480464 | Paclitaxel results in increased expression of SPARC mRNA | CTD | PMID:19682730 |
| paracetamol | affects expression | EXP | | 6480464 | Acetaminophen affects the expression of SPARC mRNA | CTD | PMID:17562736 |
| phenobarbital | affects expression | ISO | RGD:731035 | 6480464 | Phenobarbital affects the expression of SPARC mRNA | CTD | PMID:19159669 |
| piroxicam | decreases expression | ISO | RGD:731035 | 6480464 | Piroxicam results in decreased expression of SPARC mRNA | CTD | PMID:21858171 |
| raloxifene | affects expression | ISO | RGD:3742 | 6480464 | Raloxifene affects the expression of SPARC mRNA | CTD | PMID:16079270 |
| resveratrol | decreases expression | ISO | RGD:731035 | 6480464 | resveratrol results in decreased expression of SPARC mRNA; more ... | CTD | PMID:16084059 |
| resveratrol | decreases expression | ISO | RGD:3742 | 6480464 | resveratrol results in decreased expression of SPARC mRNA | CTD | PMID:19228061 |
| rosiglitazone | increases expression | ISO | RGD:3742 | 6480464 | rosiglitazone results in increased expression of SPARC mRNA | CTD | PMID:21172411 |
| streptozocin | increases expression | EXP | | 6480464 | Streptozocin results in increased expression of SPARC protein; more ... | CTD | PMID:12660331 |
| temozolomide | affects response to substance | ISO | RGD:731035 | 6480464 | SPARC mRNA affects the susceptibility to temozolomide | CTD | PMID:16365179 |
| tert-butyl hydroperoxide | decreases expression | ISO | RGD:731035 | 6480464 | tert-Butylhydroperoxide results in decreased expression of SPARC mRNA | CTD | PMID:15336504 |
| tert-butyl hydroperoxide | increases expression | ISO | RGD:731035 | 6480464 | tert-Butylhydroperoxide results in increased expression of SPARC mRNA | CTD | PMID:15963989 |
| tetrachloromethane | increases expression | ISO | RGD:3742 | 6480464 | Carbon Tetrachloride results in increased expression of SPARC mRNA | CTD | PMID:17056239 PMID:16239168 |
| tetrachloromethane | increases expression | ISO | RGD:3742 | 6480464 | Carbon Tetrachloride results in increased expression of SPARC mRNA | CTD | PMID:16239168 PMID:17056239 |
| tetrachloromethane | affects expression | EXP | | 6480464 | Carbon Tetrachloride affects the expression of SPARC mRNA | CTD | PMID:17484886 |
| trans-resveratrol | decreases expression | ISO | RGD:731035 | 6480464 | resveratrol results in decreased expression of SPARC mRNA; more ... | CTD | PMID:16084059 |
| trans-resveratrol | decreases expression | ISO | RGD:3742 | 6480464 | resveratrol results in decreased expression of SPARC mRNA | CTD | PMID:19228061 |
| trichloroethene | multiple interactions | ISO | RGD:3742 | 6480464 | [Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in decreased expression of SPARC mRNA | CTD | PMID:17905399 |
| trichloroethene | increases expression | ISO | RGD:3742 | 6480464 | Trichloroethylene results in increased expression of SPARC mRNA | CTD | PMID:19448997 |
| valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of SPARC mRNA | CTD | PMID:17963808 |
| vancomycin | decreases expression | EXP | | 6480464 | Vancomycin results in decreased expression of SPARC mRNA | CTD | PMID:18930951 |